Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,049 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group.
Herrmann R, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schüller J, Saletti P, Bauer J, Figer A, Pestalozzi B, Köhne CH, Mingrone W, Stemmer SM, Tàmas K, Kornek GV, Koeberle D, Cina S, Bernhard J, Dietrich D, Scheithauer W; Swiss Group for Clinical Cancer Research; Central European Cooperative Oncology Group. Herrmann R, et al. J Clin Oncol. 2007 Jun 1;25(16):2212-7. doi: 10.1200/JCO.2006.09.0886. J Clin Oncol. 2007. PMID: 17538165 Clinical Trial.
Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001.
Bernhard J, Dietrich D, Scheithauer W, Gerber D, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schüller J, Saletti P, Bauer J, Figer A, Pestalozzi BC, Köhne CH, Mingrone W, Stemmer SM, Tàmas K, Kornek GV, Koeberle D, Herrmann R; Central European Cooperative Oncology Group. Bernhard J, et al. Among authors: herrmann r. J Clin Oncol. 2008 Aug 1;26(22):3695-701. doi: 10.1200/JCO.2007.15.6240. J Clin Oncol. 2008. PMID: 18669454 Clinical Trial.
Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research.
Koeberle D, Saletti P, Borner M, Gerber D, Dietrich D, Caspar CB, Mingrone W, Beretta K, Strasser F, Ruhstaller T, Mora O, Herrmann R; Swiss Group for Clinical Cancer Research. Koeberle D, et al. Among authors: herrmann r. J Clin Oncol. 2008 Aug 1;26(22):3702-8. doi: 10.1200/JCO.2008.16.5704. J Clin Oncol. 2008. PMID: 18669455 Clinical Trial.
Clinical benefit response in pancreatic cancer trials revisited.
Bernhard J, Dietrich D, Glimelius B, Bodoky G, Scheithauer W, Herrmann R. Bernhard J, et al. Among authors: herrmann r. Oncol Res Treat. 2014;37(1-2):42-8. doi: 10.1159/000357965. Epub 2014 Jan 20. Oncol Res Treat. 2014. PMID: 24613908 Free article. Clinical Trial.
Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer.
Borner MM, Dietrich D, Stupp R, Morant R, Honegger H, Wernli M, Herrmann R, Pestalozzi BC, Saletti P, Hanselmann S, Müller S, Brauchli P, Castiglione-Gertsch M, Goldhirsch A, Roth AD. Borner MM, et al. Among authors: herrmann r. J Clin Oncol. 2002 Apr 1;20(7):1759-66. doi: 10.1200/JCO.2002.07.087. J Clin Oncol. 2002. PMID: 11919232 Clinical Trial.
1,049 results